Trevi Therapeutics' Phase 2b CORAL Trial Data to Be Featured at CHEST 2026

  • Trevi Therapeutics' Phase 2b CORAL trial results accepted for oral presentation at CHEST 2026 Annual Meeting.
  • Presentation scheduled for October 20, 2026, in Phoenix, Arizona, focusing on Haduvio™ (oral nalbuphine ER) for chronic cough in IPF patients.
  • CORAL trial evaluated three doses of Haduvio™ vs. placebo in 165 IPF patients over 6 weeks.
  • Primary endpoint: relative change in 24-hour cough frequency using objective cough monitors.

Trevi Therapeutics is advancing its lead candidate, Haduvio™, in a high-unmet-need indication where no FDA-approved therapies exist. The acceptance of CORAL trial data for an oral presentation at CHEST 2026 underscores the clinical relevance of Trevi's approach to chronic cough in IPF patients. The company's focus on both central and peripheral mechanisms of cough control could differentiate Haduvio™ in a growing market for respiratory therapies.

Regulatory Pathway
Whether Trevi can leverage positive Phase 2b data to accelerate FDA discussions for Haduvio™.
Market Opportunity
The pace at which Trevi can address the unmet need in IPF and RCC patients with chronic cough.
Competitive Landscape
How Trevi positions Haduvio™ against potential future competitors in the chronic cough space.